Investors Sell Danaher (DHR) on Strength (DHR)

Investors sold shares of Danaher Co. (NYSE:DHR) on strength during trading hours on Wednesday. $31.39 million flowed into the stock on the tick-up and $52.95 million flowed out of the stock on the tick-down, for a money net flow of $21.56 million out of the stock. Of all equities tracked, Danaher had the 0th highest net out-flow for the day. Danaher traded up $0.50 for the day and closed at $97.35

Several equities research analysts recently issued reports on DHR shares. Stifel Nicolaus raised their target price on shares of Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Cowen restated a “buy” rating and issued a $110.00 target price on shares of Danaher in a report on Tuesday, January 30th. UBS Group started coverage on shares of Danaher in a report on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price on the stock. Robert W. Baird restated a “buy” rating on shares of Danaher in a report on Friday, January 12th. Finally, Citigroup raised their target price on shares of Danaher to $107.00 and gave the stock a “buy” rating in a report on Friday, December 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $100.68.

The stock has a market cap of $67,960.00, a PE ratio of 27.91, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.03. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period last year, the firm earned $1.05 EPS. equities analysts forecast that Danaher Co. will post 4.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.65%. This is an increase from Danaher’s previous quarterly dividend of $0.14. The ex-dividend date of this dividend is Wednesday, March 28th. Danaher’s dividend payout ratio (DPR) is presently 16.00%.

In other news, EVP William K. Daniel sold 131,066 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the sale, the executive vice president now directly owns 270,523 shares in the company, valued at approximately $27,606,872.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Angela S. Lalor sold 42,988 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the sale, the senior vice president now owns 82,008 shares in the company, valued at $8,388,598.32. The disclosure for this sale can be found here. Insiders have sold a total of 288,123 shares of company stock worth $29,162,927 over the last 90 days. Insiders own 12.20% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. increased its holdings in Danaher by 276.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares during the last quarter. BlackRock Inc. increased its holdings in Danaher by 4.6% in the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock valued at $3,804,169,000 after acquiring an additional 1,789,474 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Danaher by 16,410.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after acquiring an additional 1,476,901 shares during the last quarter. Findlay Park Partners LLP increased its holdings in Danaher by 52.9% in the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock valued at $353,186,000 after acquiring an additional 1,425,000 shares during the last quarter. Finally, Koch Industries Inc. increased its holdings in Danaher by 29,127.3% in the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock valued at $1,388,000 after acquiring an additional 1,399,859 shares during the last quarter. Hedge funds and other institutional investors own 77.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Investors Sell Danaher (DHR) on Strength (DHR)” was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2018/02/23/investors-sell-danaher-dhr-on-strength-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply